6 research outputs found
A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and sufficient numbers are not available. Therefore, a small animal model that facilitates rapid evaluation of potential candidates for their preliminary efficacy is urgently needed in the microbicide field. We previously demonstrated that RAG-hu humanized mouse model permits HIV-1 mucosal transmission via both vaginal and rectal routes and that oral pre-exposure chemo-prophylactic strategies could be tested in this system. Here in these proof-of-concept studies, we extended this system for topical microbicide testing using HIV-1 as the challenge virus. Maraviroc, a clinically approved CCR5 inhibitor drug for HIV treatment, was formulated as a microbicide gel at 5 mM concentration in 2.2% hydroxyl ethyl cellulose. Female RAG-hu mice were challenged vaginally with HIV-1 an hour after intravaginal application of the maraviroc gel. Our results showed that maraviroc gel treated mice were fully protected against vaginal HIV-1 challenge in contrast to placebo gel treated mice which all became infected. These findings highlight the utility of the humanized mouse models for microbicide testing and, together with the recent data from macaque studies, suggest that maraviroc is a promising candidate for future microbicide clinical trials in the field
RNA and DNA viral loads in mice administered with maraviroc.
<p>RAG-hu mice were challenged by vaginal route after an hour after vaginal application of maraviroc as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020209#s2" target="_blank">Methods</a>. Blood was collected weekly. Viral RNA was extracted from the plasma fraction and DNA was extracted from the cellular fraction. Viral RNA and DNA loads were determined by Q-PCR as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020209#s2" target="_blank">methods</a>. The dotted lines represent limits of PCR detection. A. RNA viral loads B. DNA viral loads.</p
Summary of human cell engraftment levels in humanized mice<sup>*</sup>.
<p>*Peripheral blood was collected from human CD34 cell reconstituted RAG-hu mice (BALB/c-Rag2<sup>−/−</sup>γc<sup>−/−</sup> or BALB/c-Rag1<sup>−/−</sup>γc<sup>−/−</sup>, the prefix J is indicative of RAG1) at 10–12 weeks post engraftment. White blood cell fraction was stained with human CD45 FITC conjugated antibody and analyzed by FACS to confirm human cell engraftment prior to maraviroc or placebo gel treatments and vaginal HIV-1 challenges.</p
Vaginal application of maraviroc gel protects humanized mice against vaginal HIV-1 challenge.
<p>RAG-hu mice were challenged by vaginal route one hour after vaginal administration of maraviroc as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020209#s2" target="_blank">Methods</a>. Blood was collected weekly from infected mice and the status of HIV-1 infection was determined by Q-RT-PCR. Kaplan-Meier plots of time course of appearance of viremia in drug treated versus non-treated virus challenged mice.</p
Restraint validation of biomolecular structures determined by NMR in the Protein Data Bank
Biomolecular structure analysis from experimental NMR studies generally relies on restraints derived from a combination of experimental and knowledge-based data. A challenge for the structural biology community has been a lack of standards for representing these restraints, preventing the establishment of uniform methods of model-vs-data structure validation against restraints and limiting interoperability between restraint-based structure modeling programs. The NEF and NMR-STAR formats provide a standardized approach for representing commonly used NMR restraints. Using these restraint formats, a standardized validation system for assessing structural models of biopolymers against restraints has been developed and implemented in the wwPDB OneDep data deposition-validation-biocuration system. The resulting wwPDB restraint violation report provides a model vs. data assessment of biomolecule structures determined using distance and dihedral restraints, with extensions to other restraint types currently being implemented. These tools are useful for assessing NMR models, as well as for assessing biomolecular structure predictions based on distance restraints.</p
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Infectious and inflammatory diseases have repeatedly shown strong genetic associations within the major histocompatibility complex (MHC); however, the basis for these associations remains elusive. To define host genetic effects on the outcome of a chronic viral infection, we performed genome-wide association analysis in a multiethnic cohort of HIV-1 controllers and progressors, and we analyzed the effects of individual amino acids within the classical human leukocyte antigen (HLA) proteins. We identified >300 genome-wide significant single-nucleotide polymorphisms (SNPs) within the MHC and none elsewhere. Specific amino acids in the HLA-B peptide binding groove, as well as an independent HLA-C effect, explain the SNP associations and reconcile both protective and risk HLA alleles. These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection